Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-sensitive Breast Cancer Who Remain Premenopausal or Resume Menstruation After Chemotherapy: ASTRRA- IV Study

NCT07735897 is registered in ClinicalTrials.gov with MedicalExcellence as lead sponsor.

NCT NCT07735897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07735897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-sensitive Breast Cancer Who Remain Premenopausal or Resume Menstruation After Chemotherapy: ASTRRA- IV Study
Lead sponsor
MedicalExcellence
Phase
Observational
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
May 1, 2034
Enrollment
1,483 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer